Find Clinical Trials

All CategoriesMedical Conditions»Neurological Disorders»Ependymoma



Join Paid Clinical Trials



  • Conditions:   Anaplastic Ependymoma;   Ependymoma
    Intervention:   Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Ependymoma
    Interventions:   Radiation: Irradiation;   Procedure: Surgery;   Drug: ^1^8F-Fluorodeoxyglucose;   Drug: ^1^1C-methionine;   Device: Photon therapy;   Device: Proton therapy
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Recurrent Ependymoma
    Interventions:   Drug: 5-Azacytidine (5-AZA) group 1;   Drug: 5-Azacytidine (5-AZA) group 2;   Drug: 5-Azacytidine (5-AZA) group 3
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting

  • Condition:   Ependymoma
    Interventions:   Biological: HLA-A2 restricted synthetic tumor antigen;   Drug: Imiquimod;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   Ian F. Pollack, M.D.;   Solving Kids’ Cancer;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Childhood Ependymoma
    Interventions:   Drug: 16 weeks of VEC + CDDP;   Drug: VEC + HD-MTX;   Drug: Chemotherapy + Valproate;   Radiation: Conformal radiotherapy;   Drug: VEC;   Drug: Chemotherapy;   Radiation: conformal radiotherapy +/- boost
    Sponsor:   Centre Leon Berard
    Recruiting

  • Conditions:   Ependymoma;   Anaplastic Ependymoma
    Interventions:   Drug: Carboplatin;   Drug: Bevacizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Posterior Fossa Ependymoma (PFEPN)
    Interventions:   Drug: Trastuzumab after SubQ GM-CSF;   Drug: Trastuzumab in combination with SubQ GM-CSF
    Sponsors:   University of Colorado, Denver;   Children's Hospital Colorado
    Recruiting

  • Conditions:   Anaplastic Ependymoma;   Ependymoma;   Ependymomas
    Intervention:   Drug: Marizomib
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Malignant Glioma;   Ependymoma
    Intervention:   Device: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
    Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cellular Ependymoma;   Childhood Anaplastic Ependymoma;   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Clear Cell Ependymoma;   Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Papillary Ependymoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vincristine Sulfate Liposome
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Childhood CNS Tumor;   Ependymoma, Recurrent Childhood;   Childhood Solid Tumor
    Intervention:   Drug: 5 Azacytidine
    Sponsor:   The Hospital for Sick Children
    Recruiting

  • Conditions:   Constitutional Mismatch Repair Deficiency Syndrome;   Lynch Syndrome;   Malignant Glioma;   Progressive Ependymoma;   Progressive Medulloblastoma;   Recurrent Brain Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Diffuse Intrinsic Pontine Glioma;   Recurrent Medulloblastoma;   Refractory Brain Neoplasm;   Refractory Diffuse Intrinsic Pontine Glioma;   Refractory Ependymoma;   Refractory Medulloblastoma
    Interventions:   Procedure: Diffusion Tensor Imaging;   Procedure: Diffusion Weighted Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Spectroscopic Imaging;   Biological: Pembrolizumab;   Procedure: Perfusion Magnetic Resonance Imaging
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Glioblastoma Multiforme;   Astrocytoma, Grade III;   Anaplastic Ependymoma;   Clear Cell Ependymoma;   Ependymoma
    Interventions:   Biological: Heat Shock Protein Peptide Complex-96 (HSPPC-96);   Procedure: Tumor Resection;   Radiation: Radiation
    Sponsors:   Ann & Robert H Lurie Children's Hospital of Chicago;   Northwestern University
    Recruiting

  • Condition:   Brain and Central Nervous System Tumors
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Brain Metastasis;   Spinal Tumors;   Lung Tumors;   Ependymoma
    Intervention:   Radiation: SBRT treatment
    Sponsor:   Centre Leon Berard
    Recruiting

  • Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Ependymoma;   Childhood Atypical Teratoid/Rhabdoid Tumor;   Embryonal Tumor With Abundant Neuropil and True Rosettes;   Metastatic Malignant Neoplasm to the Leptomeninges
    Interventions:   Drug: Intra thecal methotrexate;   Drug: topotecan;   Drug: cyclophosphamide
    Sponsor:   Nicklaus Children's Hospital f/k/a Miami Children's Hospital
    Recruiting

  • Conditions:   High Grade Meningioma;   Ependymoma;   Medulloblastoma;   PNET;   Primary CNS Sarcoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Glioma of Brain;   Craniopharyngioma;   Ependymoma;   Germ Cell Tumor
    Interventions:   Drug: Memantine;   Other: Placebo;   Other: Cognitive Assessment
    Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Medulloblastoma;   Ependymoma;   Meningioma;   Chordoma;   Pineolblastoma
    Intervention:   Drug: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Ganglioglioma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Pleomorphic Xanthoastrocytoma, Anaplastic;   Atypical Teratoid/Rhabdoid Tumor;   Brain Cancer;   Brain Tumor;   Central Nervous System Neoplasms;   Choroid Plexus Carcinoma;   CNS Embryonal Tumor With Rhabdoid Features;   Ganglioneuroblastoma of Central Nervous System;   CNS Tumor;   Embryonal Tumor of CNS;   Ependymoma;   Glioblastoma;   Glioma;   Glioma, Malignant;   Medulloblastoma;   Medulloblastoma; Unspecified Site;   Medulloepithelioma;   Neuroepithelial Tumor;   Neoplasms;   Neoplasms, Neuroepithelial;   Papillary Tumor of the Pineal Region (High-grade Only);   Pediatric Brain Tumor;   Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only);   Pineoblastoma;   Primitive Neuroectodermal Tumor;   Recurrent Medulloblastoma;   Refractory Brain Tumor;   Neuroblastoma. CNS;   Glioblastoma, IDH-mutant;   Glioblastoma, IDH-wildtype;   Medulloblastoma, Group 3;   Medulloblastoma, Group 4;   Glioma, High Grade;   Neuroepithelial Tumor, High Grade;   Medulloblastoma, SHH-activated and TP53 Mutant;   Medulloblastoma, SHH-activated and TP53 Wildtype;   Medulloblastoma, Chromosome 9q Loss;   Medulloblastoma, Non-WNT Non-SHH, NOS;   Medulloblastoma, Non-WNT/Non-SHH;   Medulloblastoma, PTCH1 Mutation;   Medulloblastoma, WNT-activated;   Ependymoma, Recurrent;   Glioma, Recurrent High Grade;   Glioma, Recurrent Malignant;   Embryonal Tumor, NOS;   Glioma, Diffuse Midline, H3K27M-mutant;   Embryonal Tumor With Multilayered Rosettes (ETMR);   Ependymoma, NOS, WHO Grade III;   Ependymoma, NOS, WHO Grade II;   Medulloblastoma, G3/G4;   Ependymoma, RELA Fusion Positive
    Interventions:   Drug: Gemcitabine;   Drug: ribociclib;   Drug: sonidegib;   Drug: trametinib;   Biological: filgrastim
    Sponsors:   St. Jude Children's Research Hospital;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Neurofibromatosis 2;   Vestibular Schwannoma;   Meningioma;   Ependymoma;   Glioma
    Intervention:   Drug: Selumetinib
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   AstraZeneca
    Recruiting

  • Conditions:   Glioma;   Astrocytoma;   Oligodendroglioma;   Ependymoma;   Ganglioglioma;   Pleomorphic Xanthoastrocytoma
    Interventions:   Other: Part 1 Survey Group;   Other: Part 2 Focus Group
    Sponsor:   Wake Forest University Health Sciences
    Not yet recruiting

  • Conditions:   Glioblastoma Multiforme;   High-grade Astrocytoma NOS;   CNS Primary Tumor, Nos;   Ependymoma, NOS;   Diffuse Intrinsic Pontine Gliomas (DIPG);   Medulloblastoma
    Interventions:   Biological: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients;   Biological: APX005M treatment for newly diagnosed DIPG patients
    Sponsors:   Pediatric Brain Tumor Consortium;   St. Jude Children's Research Hospital;   American Lebanese Syrian Associated Charities;   The Cancer Therapy Evaluation Program of the National Cancer Institute;   Apexigen, Inc.;   Solving Kids’ Cancer;   Ty Louis Campbell Foundation;   A Kids' Brain Tumor Cure Foundation
    Recruiting

  • Conditions:   Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma;   Diffuse Intrinsic Pontine Glioma;   Primary CNS Tumor
    Interventions:   Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsor:   NewLink Genetics Corporation
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   RB1 Positive;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   NTRK1 Fusion Positive;   NTRK2 Fusion Positive;   NTRK3 Fusion Positive;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Central Nervous System Tumor, Pediatric;   Glioma;   Ependymoma;   Medulloblastoma;   Germ Cell Tumor;   Atypical Teratoid/Rhabdoid Tumor;   Primitive Neuroectodermal Tumor;   Choroid Plexus Carcinoma;   Pineoblastoma
    Intervention:   Biological: EGFR806-specific chimeric antigen receptor (CAR) T cell
    Sponsor:   Seattle Children's Hospital
    Recruiting

  • Conditions:   Central Nervous System Tumor, Pediatric;   Glioma;   Ependymoma;   Medulloblastoma;   Germ Cell Tumor;   Atypical Teratoid/Rhabdoid Tumor;   Primitive Neuroectodermal Tumor;   Choroid Plexus Carcinoma;   Pineoblastoma
    Intervention:   Biological: HER2-specific chimeric antigen receptor (CAR) T cell
    Sponsor:   Seattle Children's Hospital
    Recruiting

  • Conditions:   Central Nervous System Embryonal Tumor, Not Otherwise Specified;   Malignant Glioma;   Recurrent Atypical Teratoid/Rhabdoid Tumor;   Recurrent Childhood Ependymoma;   Recurrent Diffuse Intrinsic Pontine Glioma;   Recurrent Medulloblastoma;   Refractory Diffuse Intrinsic Pontine Glioma
    Interventions:   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ribociclib
    Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF NP_004324.2:p.V600X;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Histiocytosis;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Glioma;   Anaplastic Astrocytoma;   Anaplastic Oligoastrocytoma;   Anaplastic Oligodendroglioma;   Glioblastoma;   Gliosarcoma;   Atypical Teratoid/Rhabdoid Tumor of Brain;   Medulloblastoma;   Ependymoma;   Pleomorphic Xanthoastrocytoma of Brain;   Embryonal Tumor of Brain
    Intervention:   Biological: Polio/Rhinovirus Recombinant (PVSRIPO)
    Sponsors:   Istari Oncology, Inc.;   Solving Kids’ Cancer;   Musella Foundation for Brain Tumor Research & Information, Inc.;   The Andrew McDonough B+ Foundation;   Duke University
    Recruiting

  • Conditions:   Glioma;   Rhabdomyosarcoma;   Osteosarcoma;   Medulloblastoma;   Neuroectodermal Tumor;   Ependymoma;   Ewing's Sarcoma;   Wilms Tumor
    Interventions:   Biological: Erlotinib;   Drug: Temozolomide
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Malignant Glioma of Brain;   Astrocytoma;   Malignant Astrocytoma;   Oligodendroglioma;   Anaplastic Oligodendroglioma of Brain (Diagnosis);   Mixed Oligo-Astrocytoma;   Ependymoma;   Ganglioglioma;   Pylocytic/Pylomyxoid Astrocytoma;   Brain Tumor;   Glioma;   Brain Cancer;   Glioblastoma;   Glioblastoma Multiforme
    Interventions:   Drug: rQNestin;   Drug: Cyclophosphamide;   Procedure: Stereotactic biopsy
    Sponsors:   Dana-Farber Cancer Institute;   National Institutes of Health (NIH);   Advantagene, Inc.
    Recruiting

  • Conditions:   Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Oligodendroglioma;   Gliosarcoma;   Mixed Glioma;   Recurrent Adult Brain Neoplasm;   Recurrent Glioblastoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Brain Tumors and/or Solid Tumors Including;   Brain Stem Glioma;   High Grade CNS Tumors;   Ependymoma;   Medulloblastoma;   Craniopharyngioma;   Low Grade CNS Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Ewing Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Other
    Intervention:   Drug: Methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   ARAF Gene Mutation;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   HRAS Gene Mutation;   KRAS Gene Mutation;   MAP2K1 Gene Mutation;   MAPK1 Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Ependymal Tumor;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Pharmacokinetic Study;   Drug: Ulixertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Glioma;   Neuroectodermal Tumors, Primitive;   Wilms Tumor;   Rhabdomyosarcoma;   Sarcoma, Ewing;   Osteosarcoma;   Retinoblastoma
    Interventions:   Drug: Metronomic Cyclophosphamide;   Drug: Thalidomide
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Large Cell Lymphoma;   Refractory Childhood Acute Lymphoblastic Leukemia;   Refractory Childhood Hodgkin Lymphoma;   Refractory Childhood Malignant Germ Cell Neoplasm;   Recurrent Childhood Brain Tumor;   Recurrent Childhood Brainstem Glioma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Gliosarcoma;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Intervention:  
    Sponsors:   Florida International University;   Nicklaus Children's Hospital f/k/a Miami Children's Hospital
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   TSC1 Gene Mutation;   TSC2 Gene Mutation;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Deleterious ATM Gene Mutation;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Deleterious RAD51C Gene Mutation;   Deleterious RAD51D Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Childhood Langerhans Cell Histiocytosis;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neoplasms
    Intervention:   Drug: BXQ-350
    Sponsors:   Bexion Pharmaceuticals, LLC.;   CTI Clinical Trial and Consulting Services
    Recruiting

  • Condition:   Brain Tumor Recurrent
    Interventions:   Drug: Methotrexate;   Drug: Etoposide;   Procedure: Ommaya Reservoir
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting

  • Condition:   Brain Tumor
    Intervention:   Drug: abemaciclib
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Eli Lilly and Company
    Recruiting

  • Conditions:   Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
    Intervention:  
    Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Conditions:   Neoplasms, Brain;   Glioblastoma Multiforme;   Glioblastoma of Cerebellum;   Neoplasms;   Astrocytoma;   Astrocytoma, Cerebellar;   Neuroectodermal Tumors;   Neuroectodermal Tumors, Primitive;   Cerebellar PNET, Childhood;   Cerebellar Neoplasms;   Cerebellar Neoplasms, Primary;   Cerebellar Neoplasm, Malignant;   Cerebellar Neoplasm Malignant Primary;   Neoplasm Metastases;   Neoplasm Malignant;   Neoplasms, Neuroepithelial;   Neoplasms, Germ Cell and Embryonal;   Neoplasms by Histologic Type;   Neoplasms, Glandular and Epithelial;   Neoplasms, Nerve Tissue;   Central Nervous System Neoplasms, Primary;   Central Nervous System Neoplasms, Malignant;   Nervous System Neoplasms;   Neoplasms by Site;   Brain Diseases;   Central Nervous System Diseases;   Nervous System Diseases;   Medulloblastoma Recurrent;   HSV;   Virus;   Pediatric Brain Tumor;   Nervous System Cancer;   Primitive Neuroectodermal Tumor (PNET) of Cerebellum
    Intervention:   Biological: G207
    Sponsor:   University of Alabama at Birmingham
    Not yet recruiting

  • Conditions:   Supratentorial Neoplasms, Malignant;   Malignant Glioma;   Glioblastoma;   Anaplastic Astrocytoma;   PNET;   Cerebral Primitive Neuroectodermal Tumor;   Embryonal Tumor
    Intervention:   Biological: G207
    Sponsor:   University of Alabama at Birmingham
    Recruiting

Login to Get Started